Tissue Regenix Group Dual revenue stream growth

Hardman & Co Report Report DownloadsTissue Regenix Group Plc (LON:TRX) has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus has been on expanding in the US wound care and orthopaedic markets: in August 2017, TRX acquired CellRight Technologies, bringing in synergistic bone regeneration technology. FY’17 results will be the first to reflect the acquisition and will include 5 months of the enlarged entity. The 1H’17 results presented here are for stand-alone TRX, and show organic growth, both from the EU jv and from DermaPure, to a £1.38m total.

Strategy: To build a regenerative medicine business with a portfolio of products using the proprietary dCELL platform; underpinned by compelling clinical and economic outcomes to drive higher adoption rates; whilst retaining the strategic and corporate flexibility that the three therapeutic corporate entities provide.

Interims: TRX reported 1H’17 results to end June 2017, not affected by CellRight, with sales beating our forecast by +£0.20m to £1.38m. Net cash was better than expected at £3.61m on 30th June, subsequently strengthened by the £40m capital increase for working capital and the acquisition of CellRight.

Sales: Both DermaPure (US) and GBM-V (jv in EU) sales were above expectations by around £0.1m each. Reported growth was +118% to £1.38m (£0.63m); note, there were no jv sales in 1H’16 and the accounting date changed. Transitioning to more in-patient activity saw underlying DermaPure sales grow +13% to $1.1m.

Acquisition: Post-period end, TRX completed the acquisition of CellRight Technologies in San Antonio, Texas for up to $30m/£23m, immediately giving greater exposure to the US orthopaedic market. TRX paid 3.8x prospective EV/
sales and 12.5x EV/EBITDA for CellRight, which has traded profitably since 2014.

Investment summary: Tissue Regenix Group Plc is building commercial momentum through three clear value drivers: sales of DermaPure in US; regulatory submission of OrthoPure XT in EU; and agreement of a joint venture for commercialisation of woundcare and cardiac products in Europe. CellRight will boost FY2017 and accelerate the time to reach sustainable profitability and cash generation.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Tissue Regenix: Turning profitable and cash-generative

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of regenerative medicine products

    Hardman & Co

    Tissue Regenix: Operating leverage

    Tissue Regenix Group plc (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of regenerative medicine products for

    Hardman & Co

    Tissue Regenix: Strong 1H’22 sales suggest upside potential

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine

    Hardman & Co

    Tissue Regenix: On pathway to sustainability

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine

    Hardman & Co

    Tissue Regenix: Faster-than-anticipated recovery

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine

    Hardman & Co

    Tissue Regenix Poised for Growth (Analyst Interview)

    Tissue Regenix Group Plc (LON:TRX) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joined DirectorsTalk. Martin gives us a reminder of what Tissue Regenix does, discusses the poor operating performance,

    Hardman & Co

    Tissue Regenix: Poised for growth

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine

    Hardman & Co

    Tissue Regenix Group: Funded through to profitability

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary decellularisation technologies for repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of approved regenerative medicine products

    Hardman & Co

    Tissue Regenix Restructured to satisfy product demand

    Tissue Regenix Group (LON:TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse).

    Hardman & Co

    Tissue Regenix Credit facilities expand cash runway to 2021

    Tissue Regenix (LON: TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse).

    Hardman & Co

    Tissue Regenix Expanded GPO coverage secured

    Tissue Regenix (LON:TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse).

    Hardman & Co

    Tissue Regenix 2018 in review: foundations laid for osteobiologics

    Tissue Regenix (LON:TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse).